Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, Abruzzese E, Tiribelli M, Tieghi A, Latagliata R, Cavazzini F, Bergamaschi M, Binotto G, Crugnola M, Isidori A, Caocci G, Heidel F, Pugliese N, Bosi C, Bartoletti D, Auteri G, Cattaneo D, Scaffidi L, Trawinska MM, Stella R, Ciantia F, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Iurlo A, Vianelli N, Cavo M, Breccia M, Bonifacio M.
Palandri F, et al. Among authors: benevolo g.
Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1.
Blood Cancer J. 2021.
PMID: 33414394
Free PMC article.
No abstract available.